CRISPR’s CTX310 Rivals Regeneron Evkeeza’s LDL-C Cuts as Casgevy Hits $54M
CRISPR’s CTX310 early trials achieved LDL-C reductions comparable to Regeneron’s Evkeeza benchmarks, with CTX310 in Phase 1b and Evkeeza showing competitive target engagement. Regeneron faces growing competition as CRISPR’s Casgevy therapy generated $54 million in Q4 and tripled patient initiations to 147 in 2025, signaling potential market share shifts.
1. CRISPR’s Casgevy Uptake Surges
Casgevy generated $54 million in fourth-quarter revenue and $116 million for full year 2025, delivering infusions to 64 patients in Q4 and 147 first-time cell collections over the year, nearly tripling initiations versus 2024.
2. CTX310 Matches Evkeeza Efficacy
In Phase 1b trials, CTX310 achieved LDL-C reductions on par with Regeneron’s Evkeeza performance, while showing differentiated triglyceride lowering that could reshape cardiovascular gene editing benchmarks.
3. Competitive Pressure on Regeneron
Heightened CRISPR momentum in gene therapies for lipid disorders may challenge Regeneron’s Evkeeza market position, potentially pressuring price, uptake and prompting strategic responses in the company’s cardiovascular portfolio.